Three case studies show that combining semaglutide/tirzepatide with resistance training 3-5x/week and protein intake of 0.7-1.7 g/kg enabled lean tissue preservation (1 patient: -6.9% lean) or even gain (2 patients: +2.5%, +5.8%) despite 13-33% total weight loss.
Lean mass gained, not lost2 of 3 GLP-1 drug patients GAINED lean tissue during 13-27% weight loss by combining resistance training and adequate protein—disproving the inevitability of muscle loss
What the researchers found
Case 1: -33% weight, -53.4% fat, -6.9% lean (8.7% of loss as lean). Case 2: -26.8% weight, -61.6% fat, +2.5% lean. Case 3: -13.2% weight, -46.9% fat, +5.8% lean. Exercise: 4-7d/week, RT 3-5d/week. Protein: 0.7-1.7 g/kg BW (1.6-2.3 g/kg FFM).
Why it matters
The muscle loss concern with GLP-1 drugs has been a major criticism. These cases demonstrate that with intentional exercise and protein, lean mass can be preserved or even gained—directly countering the "Ozempic muscle" concern.
How the study worked
Case series. 3 patients (2F, 1M; BMI 32.9-51.9). Semaglutide or tirzepatide. Body composition by DXA or BIA. Exercise and protein intake tracking.
What this study cannot tell us
Only 3 patients. Self-selected motivated individuals. No control comparison. Different GLP-1 drugs and doses. Short case series.
How to read the evidence
Case series—lowest evidence but powerful individual demonstrations.
When this study was published
Published in 2025.
The bigger picture
This provides the strongest individual-level evidence that GLP-1 drug-related muscle loss is preventable with lifestyle intervention. It shifts the narrative from "GLP-1 drugs cause muscle loss" to "unsupported GLP-1 therapy causes muscle loss."
Questions still open
- What minimum exercise dose preserves lean mass on GLP-1 drugs?
- Is resistance training or protein intake more important?
- Would these results replicate in less motivated patients?
Common questions
Will I lose muscle on semaglutide?
What should I do to protect my muscles on GLP-1 drugs?
Read the original research
Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.
SAGE open medical case reports, 13, 2050313X251388724
Citation
Tinsley, Grant M; Nadolsky, Spencer. (2025). Preservation of lean soft tissue during weight loss induced by GLP-1 and GLP-1/GIP receptor agonists: A case series.. SAGE open medical case reports, 13, 2050313X251388724. https://doi.org/10.1177/2050313X251388724